We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALTO icon
151
PUT
Alto Ingredients
ALTO
$345M
$797K 0.04%
+512
New +$5.17K
IDIX
152
CALL
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$785K 0.04%
1,302
+29
+2% +$202
IMNN icon
153
Imunon
IMNN
$6.43M
$766K 0.04%
+83
New +$864K
EXAS
154
DELISTED
Exact Sciences
EXAS
$765K 0.04%
54,000
+14,271
+36% +$193K
ALKS icon
155
CALL
Alkermes
ALKS
$8.47B
$763K 0.04%
+173
New +$8.23K
EXEL icon
156
CALL
Exelixis
EXEL
$14.2B
$754K 0.04%
2,129
-1,831
-46% -$12.5K
SGYP
157
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$718K 0.04%
+377,908
New +$2.12M
ALKS icon
158
PUT
Alkermes
ALKS
$8.47B
$683K 0.04%
+155
New +$7.38K
WINT
159
DELISTED
Windtree Therapeutics Inc
WINT
$670K 0.04%
22,262
-20,595
-48% -$693K
TCRT icon
160
PUT
Alaunos Therapeutics
TCRT
$4.64M
$667K 0.04%
10
-7
-41% -$4.69K
ACHV icon
161
CALL
Achieve Life Sciences
ACHV
$634M
– –
0
– –
OCRX
162
DELISTED
Ocera Therapeutics, Inc.
OCRX
$641K 0.04%
60,726
+742
+1% +$10.6K
CYTK icon
163
CALL
Cytokinetics
CYTK
$10.8B
$628K 0.04%
661
+449
+212% +$4.06K
NWBO
164
PUT
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$628K 0.04%
868
-944
-52% -$5.6K
FURX
165
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$625K 0.04%
+7,180
New +$554K
NKTR icon
166
Nektar Therapeutics
NKTR
$2.39B
$608K 0.03%
3,345
+3,312
+10,036% +$655K
AGEN
167
Agenus
AGEN
$275M
$589K 0.03%
+9,468
New +$658K
INSM icon
168
PUT
Insmed
INSM
$22.6B
$581K 0.03%
305
-1,422
-82% -$27K
ISEE
169
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$570K 0.03%
+15,944
New +$538K
XOMA
170
PUT
DELISTED
Xoma
XOMA
$564K 0.03%
+54
New +$7.84K
TLPH icon
171
CALL
Talphera
TLPH
$67.5M
$563K 0.03%
23
-3
-12% -$711
XOMA
172
CALL
DELISTED
Xoma
XOMA
$559K 0.03%
+54
New +$7.84K
TLPH icon
173
Talphera
TLPH
$67.5M
$556K 0.03%
2,316
-1,676
-42% -$397K
VIRX
174
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$541K 0.03%
4
– –
LSTA icon
175
PUT
Lisata Therapeutics
LSTA
$10.6M
$538K 0.03%
+5
New +$5.42K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.